MedTrace Logo

Smoking Cessation Intervention: Effectiveness in Primary Care

NCT00296647 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1346

Last updated 2015-10-14

Study results available
· View outcomes & findings →

Summary

The information gathered in this study may help to develop more effective ways to help people quit smoking and stay quit in the future.

Conditions

  • Tobacco Dependence

Interventions

DRUG

nicotine patch

Decreasing dosages from 21 to 7 mg over 12 week period

DRUG

nicotine patch

Decreasing dosage from 21 to 7 mg over 12 weeks

DRUG

nicotine lozenge

4 mg nicotine lozenge: dosage according to package directions for 16 weeks

DRUG

bupropion

dosage according to prescription directions: 12 weeks

DRUG

patch + lozenge

dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)

DRUG

bupropion + lozenge

dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Thomas C Jackson, MD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2009-07-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00296647 on ClinicalTrials.gov